Bioleap, Inc

bioleap is a drug design company that leverages its proprietary technology platform to identify and optimize lead compounds where other approaches have not been successful. unlike random screening approaches, bioleap’s hypothesis-driven method is particularly effective for designing and improving lead compounds for “difficult” targets where traditional methods have failed. bioleap’s methodology conceptualizes molecules of practically infinite structural diversity and accurately predicts their relative binding affinity to a target protein. as a result, dramatically fewer compounds need to be synthesized and tested experimentally before achieving pre-clinical milestones. bioleap creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents, and generates fast-follower compounds for early market entry.